RI-AG03 (acetaat)

RI-AG03 acetate is the acetate of RI-AG03. RI-AG03 is an orally active and a BBB-penetrable Tau aggregation peptide inhibitor. RI-AG03 inhibits Tau aggregation and improves associated neurodegeneration and behavioral phenotypes in both in vivo and in vitro models. RI-AG03 can be used in the study of tauopathies such as Alzheimer's disease[1][2].

12352209

Tau Protein

Neuronal Signaling

Neurological Disease

98.22

DMSO : 2.5 mg/mL (ultrasonic)

[Ac-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-{d-Arg}-Gly-{d-Pro}-{d-Lys}-{d-Tyr}-{d-Lys}-{D-Ile}-{d-Gln}-{d-Val}-Gly-{d-Arg}-NH2(acetatesalt)]

C104H189N49O22·xC2H4O2

2477.93 (free base)

[1]Di Natale G, et al. Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease? Molecules. 2022 Aug 9;27 (16) :5066.|[2]Aggidis A, et al. A novel peptide-based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies. Alzheimers Dement. 2024 Nov;20 (11) :7788-7804.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10861A/RI-AG03-acetate-SDS-MedChemExpress.pdf

Peptides

No Development Reported